Inclusion Criteria: 

• Adult male or female participants ≥ 18 to ≤ 80 years of age.
• Diagnosis of HS (confirmed by a dermatologist[EA1] ), with a history of signs and symptoms consistent with HS for at least 6 months before the Screening Visit.
• Moderate or severe HS defined as a total of ≥ 6 inflammatory lesions (inflammatory nodules and/or abscesses) for at least 8 weeks before the Baseline Visit.
• HS lesions in at least 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline Visits.
• PPD, CTM: since some PIs are not a dermatologist, wouldn`t this part limit the enrollment? Aren`t the physicians able to diagnose HS based on the diagnosis criteria (with documented medical records of 6 months)?Alternatively, sites could request the dermatologists` records from the patients.

Exclusion Criteria: 

• Draining tunnel count of ≥ 20 at the Baseline Visit.
• Other active skin disease or condition that could interfere with HS assessments (eg, infectious or other such as cutaneous Crohn’s disease).
• Received systemic (intravenous or PO) antibiotic therapy within 8 weeks before the Baseline Visit.
  • PO doxycycline or minocycline up to 100 mg PO twice daily is permitted provided the dosing regimen has been stable for at least 8 weeks before the Baseline Visit and is expected to continue.
• Received PO or transdermal opioid analgesics (except tramadol) for any reason within 4 weeks before the Baseline Visit.
• Permitted analgesics for HS-related pain have not been at a stable dose regimen for at least 4 weeks before the Baseline Visit.
• Received prescription topical therapies for the treatment of HS within 2 weeks before the Baseline Visit.
• Received any anti-TNF-α/other biologics treatment within 12 weeks or 5 elimination half‑lives, whichever is longer, before the Baseline Visit.
• Received systemic nonbiologic therapies (eg, corticosteroids and retinoids) with potential therapeutic impact for HS within 4 weeks before the Baseline Visit.
• Received any immunomodulatory agents within 4 weeks before the Baseline Visit.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/18/2024. Questions regarding updates should be directed to the study team contact.